Drost et al. demonstrated that the Brca1 (C61G) missense mutation, which impairs BRCA1/BARD1 heterodimerization and ubiquitin ligase activity, resulted in mammary tumors that were resistant to cisplatin and PARP inhibitors compared to Brca1 null mice [25]. Here, BARD1 is linked to breast cancer.